LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

MannKind Corp

Closed

SectorHealthcare

4.52 11.33

Overview

Share price change

24h

Current

Min

4.06

Max

4.61

Key metrics

By Trading Economics

Income

-12M

668K

Sales

-1.8M

77M

P/E

Sector Avg

35.455

35.724

Profit margin

0.873

Employees

403

EBITDA

-17M

9.7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+108.63% upside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

5.2M

1.2B

Previous open

-6.81

Previous close

4.52

News Sentiment

By Acuity

72%

28%

351 / 372 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

MannKind Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 sie 2025, 22:51 UTC

Earnings

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 sie 2025, 23:57 UTC

Earnings

Trip.com Group 1H Rev $4.01B

27 sie 2025, 23:57 UTC

Earnings

Trip.com Group 1H Adj EPS $1.84

27 sie 2025, 23:57 UTC

Earnings

Trip.com Group 1H EPS $1.82

27 sie 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 sie 2025, 23:39 UTC

Earnings

Correction to Nvidia Earnings Article -- WSJ

27 sie 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 sie 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 sie 2025, 22:58 UTC

Earnings

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 sie 2025, 22:57 UTC

Earnings

South32 FY Free Cash Flow $192 Million

27 sie 2025, 22:56 UTC

Earnings

South32 FY Total Capital Expenditure $1.35 Billion

27 sie 2025, 22:56 UTC

Earnings

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 sie 2025, 22:55 UTC

Earnings

South32 Net Cash $123 Million at June 30

27 sie 2025, 22:54 UTC

Earnings

South32: Focused on Maintaining Strong Operating Momentum

27 sie 2025, 22:53 UTC

Earnings

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 sie 2025, 22:53 UTC

Earnings

South32 Extends Capital Management Program for 12 Months

27 sie 2025, 22:52 UTC

Earnings

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 sie 2025, 22:51 UTC

Earnings

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 sie 2025, 22:51 UTC

Earnings

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 sie 2025, 22:50 UTC

Earnings

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 sie 2025, 22:50 UTC

Earnings

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 sie 2025, 22:45 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 sie 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 sie 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 sie 2025, 22:43 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 sie 2025, 22:43 UTC

Earnings

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 sie 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 sie 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 sie 2025, 22:40 UTC

Earnings

Sandfire Resources Net Debt $123 Million at June 30

27 sie 2025, 22:40 UTC

Earnings

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

108.63% upside

12 Months Forecast

Average 9.43 USD  108.63%

High 12 USD

Low 7 USD

Based on 7 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

351 / 372 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.